#EULAR2020 OP0163 Updated Lupus Nephritis EULAR/ERA-EDTA Recc: 1. T2T:⬇️proteinuria 50%@6 mo,UPCR<700 mg/g@12mo 2. Class III/IV:MMF, Euro-CYP; MMF+CNI 3. goal pred < 7.5 mg/day@6 mo 4.Class IV: MMF, CNI, CTX 5. Maintain w/MMF, AZP 6.🔃renal Bx w/refract. dz @RheumNow https://t.co/tGaSIDG1ji

How long should you keep pts on TCZ for GCA after remission has been achieved? @RheumNow #eular2020

Increased severity of #COVID19 seen in bald men related to the androgens. @rheumnow Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients – the “Gabrin sign” https://t.co/T9pHuBypHp

• DEFINE_ME

#EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases receiving immunosuppressive therapies recover from COVID19" @rheumnow https://t.co/EdVLUMyHhF

#EULAR2020 panel on #COVID19 spec. situatns: 1. German regtry: very few preg rheum pts w/CV19; cases mild. 2. No info how CV19 affects APS 3. Very few ped rheum cases of CV19- cases mild; outcomes sim to gen peds pop 4. Most rheum pts w/CV19 good prognosis @rheumnow https://t.co/LQVdzJKCgu

A study worth remembering. Pts with FM-PsA had statistically higher PsA dz activity in subjective measures ONLY, not in objective measures. Make sure you take time to fully treat your patients and give them tools for FM as well as PsA. #EULAR2020 @RheumNow #AB0731 https://t.co/e3JkEmq3EZ

SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No new safety signals were identified. Check out abstract #OP0223 for the MDA/ACR50/ACR70 responses. #EULAR2020 @RheumNow https://t.co/UAx2tkKSZI

#EULAR2020 press conference report: Global Rheum Alliance for COVID19 and Eular registries provide reassurance to rheums and pts regarding immunosuppression and COVID19. The compiled data from over 600 pts in 40 countries. @RheumNow https://t.co/qMwGJTL041

• http://ow.ly/VUwb50zXWgj

Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumNow

Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6

• E-CONGRESS

Interestingly, first line use was the only predictor of improved retention of SEC in axSpA patients in this French study. Poster #THU0386 #EULAR2020 @RheumNow https://t.co/keI9xGWKCL https://t.co/avLtJzaEOc

• E-CONGRESS

This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4

Obesity is a strong predictor of worse clinical course and treatment response in AS. Poster #THU0389 #EULAR2020 @RheumNow https://t.co/Zb2RrqSIaK https://t.co/2z1HMQ3b5G

• E-CONGRESS

This Turkish study found that obesity did NOT play a roll in tx efficacy/retention using SEC in axSpA patients. #EULAR2020 Poster #THU0390 @RheumNow https://t.co/z3imYNuxYq https://t.co/sGz9cohH6T

• E-CONGRESS

Do you routinely discuss obesity with your rheum patients? #EULAR2020 @RheumNow